RXRX
Get informed when a big investor buys or sells
+ Follow| Market cap | $1.75 Billion |
|---|---|
| Enterprise Value | $1.30 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.44 |
| Beta | 1.05 |
| Outstanding Shares | 532,460,085 |
| P/E Ratio | -3.21 |
|---|---|
| PEG | 13.5 |
| Price to Sales | - |
| Price to Book Ratio | 3.44 |
| Enterprise Value to Revenue | 23.63 |
| Enterprise Value to EBIT | -2.32 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.1 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5325▼ 10.90% |
|---|---|
| Total Calls | 6,041,598▲ 31.47% |
| Total Puts | 3,217,300▲ 9.13% |
Holdings and activity of institutional investors.
| Ownership % | 69.44%▼ 5.69% |
|---|---|
| Total Invested | $1.90B▲ 84.20% |
| Investors Holding | 359▲ 8.00% |
No data
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patient...